Skysona (elivaldogene autotemecel) - MEDICAID - SOUTH CAROLINA

Skysona (elivaldogene autotemcel) gene therapy is covered as a one‑time lentiviral transduction of a patient’s hematopoietic stem cells to produce functional ALD protein and arrest progression of early, active cerebral adrenoleukodystrophy (CALD). Coverage is limited to males aged 4–17 with elevated VLCFA, gadolinium enhancement on brain MRI with a Loes score 0.5–9 and NFS ≤1, requires treatment at a certified center with prior medical director/Corporate Transplant review, and excludes patients with advanced neurologic disability, non‑cerebral ALD, females, or those outside the specified age range.

"Not eligible if Neurologic Function Score (NFS) is greater than 1."

Sign up to see full coverage criteria, indications, and limitations.